PARIS--(BUSINESS WIRE)--Commenting on the first quarter 2012 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: “In the first quarter 2012, Somatuline® and Dysport®have delivered a strong performance, respectively up 17.5%1 and 13.8%1 year-on-year, driving the growth of specialty care close to 10%1. This performance illustrates the pertinence of the chosen strategy of enhanced focus on the company’s differentiated peptides and toxins strengths.” Marc de Garidel added: “While delivering on sales, the Group is progressing on its milestones. With the US reorganization swiftly moving on, we are focused on overcoming our industrial challenges and on setting up the best sustainable solution for the Group’s French primary care activity.”
